Figure 3.
NRM. The cumulative incidence of NRM for patients receiving the phase 2 dosage of pegIFNα (n = 31).

NRM. The cumulative incidence of NRM for patients receiving the phase 2 dosage of pegIFNα (n = 31).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal